Syngene International Expands Capabilities
Syngene International, a global contract research, development and manufacturing organization (CRDMO), announces plans to add a GMP bioconjugation suite.
This new capability will enable Syngene to offer fully integrated, end-to-end services for antibody-drug conjugates (ADCs) – from discovery through to GMP manufacturing.
The bioconjugation suite will complement commercial payload, linker and monoclonal antibodies services, placing Syngene among a handful of CDMOs with full-service capabilities.
Syngene International is adding a GMP bioconjugation suite at its commercial biologics facility in Bengaluru.
Author's summary: Syngene International expands ADC development capabilities.